Literature DB >> 24511483

ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines.

Hassan Dariushnejad1, Nosratallah Zarghami2, Mohammad Rahmati2, Samaneh Ghasemali1, Zohreh Sadeghi1, Zahra Davoodi1, Hossein Jafari Tekab3, Masoud Gandomkar Ghalhar1.   

Abstract

PURPOSE: Intensive chemotherapy with daunorubicin (DNR) is associated with serious side effects in acute myeloid leukemia (AML) patients. In this study the effect of small-molecule BH3-mimetic, ABT-737, on the sensitivity of HL60 and U937 AML cell lines was investigated.
METHODS: The cytotoxic effects of DNR and ABT-737, alone or in combination were assessed using MTT assay and combination index analysis. The effects of treatments on the cell proliferation was determined by trypan blue assay. ELISA cell death assay was used for measurement of apoptosis.
RESULTS: IC50 values of DNR and ABT-737 were 2.52 and 0.59 µM for HL-60 cells line and 1.31 and 0.80 µM for U937 cell line at 24 h, respectively. Surprisingly, combination treatment significantly lowered the IC50 values in a synergic manner in both cell lines. Moreover, treatment with a mixture of two agents had more growth inhibition effect relative to the monotherapy. RESULTS of apoptosis assay showed that the cytotoxic effects are related to the enhancement of apoptosis.
CONCLUSION: Our study suggests that ABT-737 synergistically enhances the cytotoxic effect of DNR in AML cell lines and therefore may be useful to overcome chemoresistance of leukemia patients.

Entities:  

Keywords:  ABT-737; Acute myeloid leukemia; Apoptosis; Combination; Daunorubicin

Year:  2013        PMID: 24511483      PMCID: PMC3915819          DOI: 10.5681/apb.2014.027

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  25 in total

1.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

Authors:  Shuang Chen; Yun Dai; Hisashi Harada; Paul Dent; Steven Grant
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

2.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

Authors:  Stephen K Tahir; Xiufen Yang; Mark G Anderson; Susan E Morgan-Lappe; Aparna V Sarthy; Jun Chen; Robert B Warner; Shi-Chung Ng; Stephen W Fesik; Steve W Elmore; Saul H Rosenberg; Christin Tse
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

3.  'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Authors:  X Lin; S Morgan-Lappe; X Huang; L Li; D M Zakula; L A Vernetti; S W Fesik; Y Shen
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

4.  Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.

Authors:  Emilie Varin; Christophe Denoyelle; Emilie Brotin; Matthieu Meryet-Figuière; Florence Giffard; Edwige Abeilard; Didier Goux; Pascal Gauduchon; Philippe Icard; Laurent Poulain
Journal:  Carcinogenesis       Date:  2010-02-08       Impact factor: 4.944

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

Review 6.  Current and emerging therapies for acute myeloid leukemia.

Authors:  Tadeusz Robak; Agnieszka Wierzbowska
Journal:  Clin Ther       Date:  2009       Impact factor: 3.393

7.  Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.

Authors:  Chunhong Gu; Teng Ye; Richard A Wells
Journal:  Leuk Res       Date:  2006-05-15       Impact factor: 3.156

8.  Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells.

Authors:  Hideko Akagi; Hajime Higuchi; Hidetoshi Sumimoto; Toru Igarashi; Ayano Kabashima; Hiroyuki Mizuguchi; Motoko Izumiya; Gen Sakai; Masayuki Adachi; Shinsuke Funakoshi; Shoko Nakamura; Yasuo Hamamoto; Takanori Kanai; Hiromasa Takaishi; Yutaka Kawakami; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2012-04-24       Impact factor: 7.370

Review 9.  The role of cytokines in acute myeloid leukemia: a systematic review.

Authors:  Tomas Kupsa; Jan Milos Horacek; Ladislav Jebavy
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2012-12-07       Impact factor: 1.245

10.  Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

Authors:  Veerle Kersemans; Bart Cornelissen; Mark D Minden; Joseph Brandwein; Raymond M Reilly
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

View more
  3 in total

1.  The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.

Authors:  Denis V Baev; Janusz Krawczyk; Michael O׳Dwyer; Eva Szegezdi
Journal:  Leuk Res Rep       Date:  2014-09-01

Review 2.  The application of BH3 mimetics in myeloid leukemias.

Authors:  Narissa Parry; Helen Wheadon; Mhairi Copland
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

3.  Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC.

Authors:  Marion Gilormini; Céline Malesys; Emma Armandy; Patrick Manas; Jean-Baptiste Guy; Nicolas Magné; Claire Rodriguez-Lafrasse; Dominique Ardail
Journal:  Oncotarget       Date:  2016-03-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.